Liposomal Clodronate as a Therapy for Autoimmune Hemolytic Anemia

Tech ID: 02-07

NOTE: THIS TECHNOLOGY IS EXPERIMENTAL AND THEREFORE IT IS NOT AVAILABLE TO HUMANS. IT HAS ONLY BEEN TESTED IN MICE AND DOGS DIAGNOSED WITH AIHA

Summary - This invention is using liposomal clodronate as a therapy for autoimmune hemolytic anemia (AIHA).

Potential Applications

  • Therapy for autoimmune hemolytic anemia
  • The therapy is applicable to both humans and companion animals

Advantages of Invention

  • The method is less invasive than surgery (splenectomy)
  • Decrease use of steroids
  • Decrease side effects

State of Development

  • The efficacy of this therapy has been demonstrated by some strong in vivo data obtained in mice and dogs with AIHA.
  • Using a mouse model in which animals were given anti red blood cell antibodies, treatment with liposomal clodronate substantially decreased red blood cell destruction.
  • In addition, this effect was detected within hours and lasted at least a week.

Further R&D Required - Additional in vivo studies with other animal models.

02-07a

RBC clearance and the effects of LC treatment in dogs with AIHA. RBC clearance in 6 dogs with spontaneous AIHA was assessed by flow cytometry prior to treatment and again 24 hours after treatment with LC and the mean (± SE) percentage of labeled RBC present in circulation at each time point post infusion was determined. (B) RBC clearance kinetics were determined again 24 hours after treatment with 0.5 mL/kg LC. In 4 dogs (Nonresponders), there was no change in RBC clearance compared to clearance prior to treatment with LC, whereas in 2 dogs (Responders), RBC clearance was markedly reduced.

Publications

  • Jordan, M. B., John Kappler, and Pippa Marrack. "Liposomal Clodronate as a Novel Agent for Treating Autoimmune Hemolytic Anemia in a Mouse Model." Blood 101.2 (2002): 594-601. Print. PMID:  12393630.
  • Mathes, Mark, Michael Jordan, and Steven Dow. "Evaluation of Liposomal Clodronate in Experimental Spontaneous Autoimmune Hemolytic Anemia in Dogs." Experimental Hematology 34.10 (2006): 1393-402. Print. PMID: 16982332.


Inventors - Mike Jordan, MD, Philippa Marrack, PhD and John Kappler, PhD

Patent Status - U.S. Patent #7,090,865.

Licensing Potential - Available for licensing.

 

For Further Information, Contact:
Emmanuel Hilaire, PhD
Manager
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: 303.398.1262
Fax: 303.270.2352
HilaireE@njhealth.org

Bookmark and Share

Faculty by Research

The discoveries made in the laboratories at National Jewish Health have a profound impact on the understanding and treatment of human disease.

Browse our Faculty by Area of Research.